In Vitro Activity of Ceftazidime/Avibactam Against Multidrug-Resistant Gram-Negative Bacilli in Niger.

Massir Issoufou Noma, Abdourahamane Yacouba, Ounoussa Tapha, Harouna Moussa, Abdoulaye Ousmane, Souleymane Brah, Mahamadou Doutchi, Maman Laminou Ibrahim

Abstract readReview

PubMed Full text at PMC

In one paragraph

Review in Nigerian medical journal : journal of the Nigeria Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Massir Issoufou NomaLaboratoire National de Référence sur la Résistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger.

Abdourahamane YacoubaLaboratoire National de Référence sur la Résistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger.

Ounoussa TaphaLaboratoire National de Référence sur la Résistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger.

Harouna MoussaLaboratoire National de Référence sur la Résistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger.

Abdoulaye OusmaneDépartement des Sciences Biologiques Appliquées, Faculté des Sciences de la Santé, Université Dan Dicko Dankoulodo, Maradi, Niger.

Souleymane BrahLaboratoire National de Référence sur la Résistance aux Antimicrobiens, Hôpital National Amirou Boubacar Diallo, Niamey, Niger.

Mahamadou DoutchiDépartement de Médecine et Spécialités Médicales, Faculté des Sciences de la Santé, Université André Salifou, Zinder, Niger.

Maman Laminou IbrahimCentre de Recherche Médicale et Sanitaire, Niamey, Niger.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The rise of multidrug-resistant Gram-negative bacilli (MDR-GNB) necessitates the evaluation of new antibiotics such as ceftazidime-avibactam (CZA). Data on its efficacy in Niger is scarce. This study assessed the in vitro activity of CZA against clinical MDR-GNB isolates. Methodology: This prospective cross-sectional study was carried out on 306 non-duplicate MDR-GNB isolates from a National Reference Laboratory from December 2023 to November 2024. Antimicrobial susceptibility testing was performed, and CZA resistance rates were determined. Statistical analysis identified factors associated with resistance. Results: Overall, 23.4% of MDR isolates were resistant to CZA. However, resistance varied dramatically by phenotype: 7.6% in ESBL-producing Enterobacterales (ESBL-E), 33.3% in carbapenem-resistant Conclusion: CZA demonstrates potent activity against ESBL-E in Niger, supporting its role as a carbapenem-sparing agent. However, the high resistance rates in CRE and CRAB preclude its empirical use for suspected infections with these pathogens. These findings underscore the critical need for routine CZA susceptibility testing and enhanced stewardship to preserve its utility.

Indexed as

Ceftazidime/AvibactamGram-negative bacilliMultidrug-resistantNiger

Identifiers

PMID42605433

PMCPMC13477690

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.